6 results on '"Peuvrel L"'
Search Results
2. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
- Author
-
Chasseuil E, Saint-Jean M, Chasseuil H, Peuvrel L, Quéreux G, Nguyen JM, Gaultier A, Varey E, Khammari A, and Dréno B
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal adverse effects, Antineoplastic Agents, Immunological adverse effects, C-Reactive Protein metabolism, Clinical Decision-Making, Disease-Free Survival, Female, France, Humans, L-Lactate Dehydrogenase blood, Leukocyte Count, Lymphocytes, Male, Melanoma blood, Melanoma mortality, Melanoma pathology, Middle Aged, Monocytes, Multivariate Analysis, Neutrophils, Nivolumab, Patient Selection, Pilot Projects, Predictive Value of Tests, Proportional Hazards Models, Retrospective Studies, Skin Neoplasms blood, Skin Neoplasms mortality, Skin Neoplasms pathology, Time Factors, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Biomarkers, Pharmacological blood, Biomarkers, Tumor blood, Leukocytes, Melanoma drug therapy, Skin Neoplasms drug therapy
- Abstract
Nivolumab response rate is 40% in metastatic melanoma. Few studies have evaluated pre-treatment biomarkers predictive of response. The aim of this study was to identify potential peripheral blood biomarkers associated with survival in patients with advanced melanoma treated with nivolumab. All advanced melanoma cases treated with anti-programmed cell death protein 1 (anti-PD1) over a 3-year period in the Dermato-Oncology Department, Nantes, France were identified. For each case, 9 potential blood biomarkers were identified. Bivariate and multivariate analyses, adjusted for the American Joint Committee on Cancer (AJCC) classification stage, Eastern Cooperative Oncology Group (ECOG) performance status, lactate dehydrogenase (LDH) level and failure to respond to first-line therapy, were used to test the association between biomarkers and overall survival (primary outcome) or progression-free survival (secondary outcome). Increased monocyte count, leukocyte/lymphocyte ratio and neutrophil/lymphocyte ratio were significantly associated with decreased overall survival after bivariate and multivariate analyses. Increased monocyte count was also significantly associated with decreased progression-free survival. These blood variables are easily measured and could help to predict patient response before the introduction of anti-PD1 therapy.
- Published
- 2018
- Full Text
- View/download PDF
3. Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients.
- Author
-
Saint-Jean M, Knol AC, Volteau C, Quéreux G, Peuvrel L, Brocard A, Pandolfino MC, Saiagh S, Nguyen JM, Bedane C, Basset-Seguin N, Khammari A, and Dréno B
- Subjects
- Cells, Cultured, Female, Follow-Up Studies, Forkhead Transcription Factors metabolism, Humans, Interleukin-2 metabolism, Lymphocytes, Tumor-Infiltrating transplantation, Male, Melanoma mortality, Melanoma pathology, Neoplasm Staging, Remission Induction, Retrospective Studies, Survival Analysis, T-Lymphocytes, Regulatory transplantation, Antibodies, Monoclonal therapeutic use, Immunotherapy, Adoptive methods, Lymphocytes, Tumor-Infiltrating immunology, Melanoma therapy, T-Lymphocytes, Regulatory immunology
- Abstract
Immunotherapy for melanoma includes adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs). This monocenter retrospective study was undertaken to evaluate the efficacy and safety of this treatment of patients with advanced melanoma. All advanced melanoma patients treated with TILs using the same TIL expansion methodology and same treatment interleukin-2 (IL-2) regimen between 2009 and 2012 were included. After sterile intralesional excision of a cutaneous or subcutaneous metastasis, TILs were produced according to a previously described method and then infused into the patient who also received a complementary subcutaneous IL-2 regimen. Nine women and 1 man were treated for unresectable stage IIIC ( n = 4) or IV ( n = 6) melanoma. All but 1 patient with unresectable stage III melanoma (1st line) had received at least 2 previous treatments, including anti-CTLA-4 antibody for 4. The number of TILs infused ranged from 0.23 × 10
9 to 22.9 × 109 . Regarding safety, no serious adverse effect was reported. Therapeutic responses included a complete remission, a partial remission, 2 stabilizations, and 6 progressions. Among these 4 patients with clinical benefit, 1 is still alive with 9 years of follow-up and 1 died from another cause after 8 years of follow-up. Notably, patients treated with high percentages of CD4 + CD25 + CD127lowFoxp3+ T cells among their TILs had significantly shorter OS. The therapeutic effect of combining TILs with new immunotherapies needs further investigation.- Published
- 2018
- Full Text
- View/download PDF
4. Three new cases of bullous pemphigoid during anti-PD-1 antibody therapy.
- Author
-
Le Naour S, Peuvrel L, Saint-Jean M, Dreno B, and Quereux G
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal adverse effects, Female, Humans, Male, Middle Aged, Neoplasms complications, Pemphigoid, Bullous immunology, Antibodies, Monoclonal therapeutic use, Autoantibodies immunology, Neoplasms therapy, Pemphigoid, Bullous etiology, Programmed Cell Death 1 Receptor immunology
- Published
- 2018
- Full Text
- View/download PDF
5. Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab.
- Author
-
Frenard C, Peuvrel L, Jean MS, Brocard A, Knol AC, Nguyen JM, Khammari A, Quereux G, and Dreno B
- Subjects
- Antibodies, Monoclonal administration & dosage, Brain Neoplasms immunology, Disease Progression, Female, Humans, Ipilimumab, Male, Melanoma immunology, Middle Aged, Retrospective Studies, Survival Analysis, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Brain Neoplasms drug therapy, Brain Neoplasms secondary, Melanoma drug therapy, Melanoma pathology
- Abstract
Unlabelled: Ipilimumab is a monoclonal antibody blocking the inhibitory molecule CTLA4 expressed by activated T lympocytes, used for the treatment of metastatic melanoma. Recent studies have shown its potential efficacy on brain metastases., Objectives: To assess the development of brain metastases under ipilimumab and identify clinical, histological or evolving criteria related to the appearance of these metastases. A retrospective study was conducted in 52 patients treated with 4 cycles of ipilimumab 3 mg/kg every 3 weeks for unresectable stage III or stage IV melanoma between January 2011 and July 2013 in a Department of Dermato-Oncology. As no data has been find in the literature, the results were compared to our other cohort of patients treated with vemurafenib during the same period. Ten patients (21.7 %) developed brain metastases under ipilimumab in a median time of 6.58 months after treatment initiation. The multivariate analysis showed a lower rate of brain metastases in patients with acral lentiginous melanoma and melanoma of unknown primary site. The median survival after diagnosis of brain metastases was of 2.5 months. There was no significant difference with vemurafenib-treated patients in terms of incidence rate of brain metastasis, time of development and survival after diagnosis of cerebral metastases. This was the first study focused on the development of brain metastases under treatment with ipilimumab 3 mg/kg. Although ipilimumab is used for the treatment of brain metastases, it paradoxically did not seem to reduce the risk of developing brain metastases.
- Published
- 2016
- Full Text
- View/download PDF
6. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma.
- Author
-
du Rusquec P, Saint-Jean M, Brocard A, Peuvrel L, Khammari A, Quéreux G, and Dréno B
- Subjects
- Aged, Antibodies, Monoclonal adverse effects, CTLA-4 Antigen immunology, Female, Humans, Immunoglobulins, Intravenous administration & dosage, Ipilimumab, Leukocyte Count, Melanoma complications, Melanoma immunology, Monitoring, Physiologic, Neoplasm Metastasis, Recovery of Function, Skin Neoplasms complications, Skin Neoplasms immunology, Antibodies, Monoclonal administration & dosage, Autoimmune Diseases etiology, Immunotherapy adverse effects, Melanoma therapy, Pancytopenia etiology, Skin Neoplasms therapy
- Abstract
A 77-year-old patient treated with ipilimumab (anti-CTLA-4 antibody) for metastatic melanoma developed autoimmune pancytopenia (anemia, thrombocytopenia, and neutropenia) 8 days after the fourth infusion. This pancytopenia was resistant to high-dose oral corticosteroids (1 mg/kg) and to hematopoietic growth factors. It resolved after intravenous immunoglobulins injection. To date, only 1 case of autoimmune pancytopenia has been reported after this treatment. According to the case that we report, it seems essential to control the leukocyte count before any injection of ipilimumab.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.